You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

~ Buy the IXEMPRA KIT (ixabepilone) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR IXEMPRA KIT

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for IXEMPRA KIT

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00021099 ↗	Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2001-06-01	Phase II trial to study the effectiveness of ixabepilone in treating patients who have progressive or metastatic urinary tract cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
NCT00022542 ↗	BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma	Terminated	National Cancer Institute (NCI)	Phase 2	2001-06-01	Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced soft tissue sarcoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00023946 ↗	BMS-247550 in Treating Patients With Liver or Gallbladder Cancer	Terminated	National Cancer Institute (NCI)	Phase 2	2001-08-01	Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver or gallbladder cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00025155 ↗	Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy	Completed	Gynecologic Oncology Group	Phase 2	2002-07-01	Phase II trial to study the effectiveness of ixabepilone in treating patients who have recurrent or persistent ovarian epithelial or primary peritoneal cancer that has not responded to previous chemotherapy. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
NCT00025155 ↗	Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy	Completed	National Cancer Institute (NCI)	Phase 2	2002-07-01	Phase II trial to study the effectiveness of ixabepilone in treating patients who have recurrent or persistent ovarian epithelial or primary peritoneal cancer that has not responded to previous chemotherapy. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
NCT00028561 ↗	BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors	Terminated	National Cancer Institute (NCI)	Phase 1	2001-10-01	This phase I trial is studying the side effects and best dose of BMS-247550 when given together with carboplatin in treating patients with recurrent or refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells
NCT00033618 ↗	Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck	Completed	National Cancer Institute (NCI)	Phase 2	2002-11-01	Randomized phase II trial to study the effectiveness of ixabepilone in treating patients who have metastatic or recurrent head and neck cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for IXEMPRA KIT

Condition Name

Chart
Table

Condition Name for IXEMPRA KIT
Intervention	Trials
Metastatic Breast Cancer	8
Breast Cancer	7
Stage IV Breast Cancer	6
Recurrent Breast Cancer	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for IXEMPRA KIT
Intervention	Trials
Breast Neoplasms	21
Carcinoma	11
Neoplasms	7
Adenocarcinoma	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for IXEMPRA KIT

Trials by Country

Map
Table

Trials by Country for IXEMPRA KIT
Location	Trials
United States	337
Japan	18
Italy	18
United Kingdom	15
Brazil	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for IXEMPRA KIT
Location	Trials
Maryland	17
California	15
Florida	15
Illinois	13
Missouri	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for IXEMPRA KIT

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for IXEMPRA KIT
Clinical Trial Phase	Trials
Phase 3	5
Phase 2	33
Phase 1/Phase 2	5
[disabled in preview]	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for IXEMPRA KIT
Clinical Trial Phase	Trials
Completed	39
Terminated	9
Active, not recruiting	5
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for IXEMPRA KIT

Sponsor Name

Chart
Table

Sponsor Name for IXEMPRA KIT
Sponsor	Trials
National Cancer Institute (NCI)	27
Bristol-Myers Squibb	17
R-Pharm	15
[disabled in preview]	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for IXEMPRA KIT
Sponsor	Trials
Industry	39
NIH	27
Other	22
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.